Estado federal brasileiro

Divulgação dos SUMÁRIOS das obras recentemente incorporadas ao acervo da Biblioteca Ministro Oscar Saraiva do STJ. Em respeito à Lei de Direitos Autorais, não disponibilizamos a obra na íntegra.Localização na estante: 342.24(81) S237

Comentários à Constituição brasileira de 1988

Divulgação dos SUMÁRIOS das obras recentemente incorporadas ao acervo da Biblioteca Ministro Oscar Saraiva do STJ. Em respeito à Lei de Direitos Autorais, não disponibilizamos a obra na íntegra.Localização na estante: 342.4(81)"1988" Coment. S237

Evaluation of the bioequivalence of two formulations containing the combination of 400 mg of acetaminophen (paracetamol), 4 mg of phenylephrine and 4 mg of chlorpheniramine in capsules: open-label, three-way crossover study, partially replicated in health

This study was carried out in order to compare the relative bioavailability of two different formulations containing 400 mg of acetaminophen + 4 mg of phenylephrine hydrochloride + 4 mg of chlorpheniramine maleate, Test formulation (Cimegripe®) and Reference formulation (Resfenol®) in 84 healthy volunteers of both sexes under fasting conditions. The study was conducted in a single dose, randomized, open-label, crossover 3-way and partially replicated. The tolerability was evaluated by the monitoring of adverse events and vital signs, results of clinical and laboratory tests. Plasma concentrations were quantified by validated bioanalytical methods using the ultra-performance liquid chromatography coupled to tandem mass spectrometry. The Cmax, Tmax, AUC0-t, AUC0-inf, T1/2 and Kel pharmacokinetic parameters were calculated from these obtained concentrations. The 90% confidence intervals were constructed for the ratio reference/test from the geometric average of the Cmax and AUC parameters which were comprised between 80% and 125%. Only the Cmax parameter of the phenylephrine was applied the scaled average bioequivalence due to the intraindividual coefficient of variation > 30% obtained, thus extending the acceptance limits of the interval. It can be concluded that the two formulations were bioequivalent in terms of rate and absorption extent and thus interchangeable

O videomonitoramento na vigilância externa dos estabelecimentos penais e os reflexos na atividade de polícia de guarda / Video surveillance in the external surveillance of penal establishments and the effects on the guard police activity

O presente trabalho tem por objetivo abordar aspectos práticos envolvendo a execução do serviço de guarda externa das unidades penais no Paraná. Essa execução se dá em um contexto que imprime a todos os segmentos da atividade humana a inovação por meio da tecnologia, o trabalho executado pela Polícia Militar do Paraná se ressente da falta de um sistema de videomonitoramento por câmeras. Tomando como ponto de partida as unidades penais instaladas em Piraquara, PR, pretende este breve estudo apontar a incrementação tecnológica como fator preponderante para desembaraço de efetivos e minimização de custos, com a conseqüente redução da exposição das sentinelas a riscos decorrentes da guarda.

Quantification of dexchlorpheniramine and betamethasone in human plasma by the uplc-ms/ms method and its application in a bioequivalence study containing the two drugs in combination, administered as a single dose in healthy volunteers/ Quantificação de dexclorfeniramina e betametasona em plasma humano pelo método clue-em/em e sua aplicação em um estudo de bioequivalência contendo os dois fármacos em associação, administrados em dose única em voluntários sadios

This study was carried out in order to compare the relative bioavailability of two different formulations containing 2.00 mg of dexchlorpheniramine maleate + 0.25 mg of bethametasona, test formulation (Dexmine®) and reference formulation (Celestamine®) in healthy volunteers of both sexes under fasting conditions. The study was conducted in a single dose, randomized, open-label, crossover 2 x 2. The tolerability was evaluated by the monitoring of adverse events and vital signs, results of clinical and laboratory tests. Plasma concentrations were quantified by validated bioanalytical method employed the ultra-performance liquid chromatography triple quadrupole tandem mass spectrometry, using as the internal standard brompheniramine. Non-compartmental model was applied to determine different pharmacokinetic parameters and these were calculated from the plasma concentrations obtained from the volunteer samples. Bioequivalence between test and reference formulation were demonstrated as the calculated 90 % confidence interval for the corresponding ratios of log transformed pharmacokinetic parameters (Cmax, AUC0-t and AUC0-?) fell within the 80–125 % range, the predetermined criterion for therapeutic equivalence. It can be concluded that the two formulations were bioequivalent in terms of rate and absorption extent and thus interchangeable

Study of bioequivalence between two formulations containing dipyrone 300 mg + isometheptene mucate 30 mg + caffeine 30 mg: a randomized, open-lable, two period crossover study in healthy adult Brazilian volunteers/ Bioequivalência entre duas formulações contendo 300 mg de dipirona + 30 mg de mucato de isometepteno + cafeína 30 mg: um estudo cruzado randomizado, aberto e de dois períodos, em voluntários brasileiros adultos saudáveis

The combination of dipyrone 300 mg, isometheptene mucate 30 mg and caffeine 30 mg in a single tablet is widely used in Brazil for the acute treatment of various forms of primary headaches. This study aimed to evaluate the bioequivalence between two formulations containing the combination of these active ingredients. An open-label, randomized, single-dose, two-period, two-sequence, two-treatment crossover study was conducted in 80 healthy subjects of both genders. Subjects received a single dose of test coated tablet (Sedamed®, Cimed Indústria de Medicamentos Ltda.) and reference product (Neosaldina®, Nycomed Pharma Ltda.) under fasting conditions according to a randomly assigned order with a 7-day washout period. Serial blood samples were collected up to 24h post-dose. Plasma concentrations of active pharmaceutical ingredients were obtained by a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters were calculated using non-compartmental methods. There were no serious adverse events during the study and both formulations were safe and well tolerated during the study. Geometric mean ratios (90% confidence intervals) for Cmax and AUC0-t were 97.04% (94.94 – 99.19) and 98.77% (95.58 – 102.06) for 4-MAA and 100.12% (93.33 – 107.41) and 96.19% (91.24 – 101.42) for isometheptene, respectively. The test formulation of was considered bioequivalent to reference product according to regulatory requirements, and therefore interchangeable

A PCSK9 e sua relevância clínica com os novos alvos terapêuticos contra a dislipidemia

This is a remarkable progress; since the finding of statins, there was no new way of reducing, significantly, cholesterol and LDL fraction. It is also clear that this decrease, by statins, is related to future cardiovascular lesions, being useful in its primary and secondary prophylaxis. The authors presented studies on research to promote the falling of blood cholesterol by means of antibodies, which inhibit the pro-protein PCSK9, as well as agents that act performing the RNA interference. We had two advantages immediately: for patients with myopathy associated with statins, and the fact of being injected every 15 days, that may contribute to better treatment adherence.Este é um progresso sensível; desde a descoberta das estatinas, não havia novas maneiras de diminuir, de maneira significativa, o colesterol e a fração LDL. Também está claro que essa redução, pelas estatinas, tem relação com futuras lesões cardiovasculares, sendo útil na profilaxia primária e secundária destas. Os autores apresentaram estudos sobre pesquisas para promover a queda do colesterol sanguíneo por meio de anticorpos que inibem a pró-proteína PCSK9, bem como agentes que atuam realizando a interferência no RNA. Duas vantagens se afiguram imediatamente: para pacientes que têm a miopatia relacionada às estatinas e por ser droga injetável a cada 15 dias, o que pode colaborar para maior adesão ao tratamento.Hospital Israelita Albert EinsteinUniversidade Federal de São Paulo (UNIFESP)UNIFESPSciEL